CRISPR Assays for Disease Diagnosis: Progress to and Barriers Remaining for Clinical Applications
Abstract
Numerous groups have employed the special properties of CRISPR/Cas systems to develop platforms that have broad potential applications for sensitive and specific detection of nucleic acid (NA) targets. However, few of these approaches have progressed to commercial or clinical applications. This review summarizes the properties of known CRISPR/Cas systems and their applications, challenges associated with the development of such assays, and opportunities to improve their performance or address unmet assay needs using nano‐/micro‐technology platforms. These include rapid and efficient sample preparation, integrated single‐tube, amplification‐free, quantifiable, multiplex, and non‐NA assays. Finally, this review discusses the current outlook for such assays, including remaining barriers for clinical or point‐of‐care applications and their commercial development.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 10, 2023
- Source ID
- 10.1002/advs.202301697
Entities
People
- Christopher J. Lyon
- Jin Wang
- Shuihua Lu
- Tony Y. Hu
- Zhen Huang
Organizations
- National Institutes of Health
- Southern University of Science and Technology
- Tulane University of Louisiana
- United States Department of Defense